Milnacipran; Mildacipran; Antidrepssant; Amitriptyline; Major Depression; F 2207
Abstract :
[en] A multicenter study compared the antidepressant efficacy and the tolerance of two doses of milnacipran (50 mg and 100 mg/day) and amitriptyline (150 mg/day) in three parallel groups of 45 major depressive inpatients defined by Research Diagnostic Criteria. After a wash-out period of 4-7 days on placebo with lorazepam and/or nitrazepam if necessary, patients were randomly assigned to a daily dose of milnacipran 50 mg, milnacipran 100 mg or amitriptyline 150 mg reached on the 5th day and then stable over a 4-week period, with weekly assessments by means of the Montgomery and Asberg depression scale, the Hamilton depression scale, the Clinical Global Impressions (CGI) and the Target Emergent Signs and Symptoms. Results showed significant superiority of both milnacipran 100 mg/day and amitriptyline over milnacipran 50 mg/day at the end of the treatment period. However, amitriptyline induced a nonsignificant trend toward more rapid improvement after 2 weeks of treatment, mainly based on items related to insomnia, supporting more sedative properties of amitriptyline as compared to milnacipran. Anticholinergic side-effects were significantly lower with milnacipran than with amitriptyline, explaining why milnacipran 100 mg exhibited at the end of the treatment period, a nonsignificantly better efficacy index on the CGI. Moreover, in contrast to milnacipran, amitriptyline was responsible for a significant decrease in blood pressure and a significant weight gain.
Disciplines :
Treatment & clinical psychology
Author, co-author :
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
von Frenckell, Rémy ; Université de Liège - ULiège > Psychiatrie et psychologie médicale
Mertens, C.
de Wilde, J.
Botte, L.
Devoitille, J. M.
Evrard, J. L.
De Nayer, A.
Orban, Pierre ; Université de Liège - ULiège > Centre de recherches du cyclotron
Dejaiffe, G.
Language :
English
Title :
Controlled Comparison of Two Doses of Milnacipran (F 2207) and Amitriptyline in Major Depressive Inpatients
Ansseau M., Anso C., Beckers G., Bogaert M., Botte L., De Buck R., Diricq S., Dumortier A., Jansegers E., Owieczka J., Stellamans G. (1984) Double-blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J Affective Disord 7:287-296.
Covi L., Lipman R., McNair D.M., Czerlinski T. (1979) Symptomatic volunteers in multicenter drug trials. Prog Neuropsychopharmacol 3:521-533.
Enelow A.J. (1975) Amitriptyline in the management of depression: an overview. Amitriptyline in the management of depression , Merck Sharp and Dohme, West Point, PA; 139-161.
Feighner J.P. (1986) The new generation of antidepressants. Depression: basic mechanisms, diagnosis, and treatment , A.J., Rush, K.Z., Altschuler, Guildford Press, New York; 205-225.
ECDEU Assessment manual for psychopharmacology (revised), W., Guy, National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD; 1976.
Hamilton M. (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 12:56-62.
Lenox R.H., Shipley J.E., Peyser J.M., Willia J.M., Weaver L.A. (1984) Double-blind comparison of alprazolam versus imipramine in the inpatient treatment of major depressive illness. Psychopharmacol Bull 20(1):79-82.
Montgomery A., Asberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
Moret C., Charveron M., Finberg J.P.M., Couzinier J.P., Briley M. (1985) Biochemical profile of midalcipran (F 2207), l-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24:1211-1219.
Raskin A., Schulterbrandt J., Reatig N., Rice C.E. (1967) Factors of psychopathology in interview, word behavior and self-report ratings of hospitalized depressions. J Consult Psychol 31:270-278.
Rush A.J., Erman M.K., Schlesser M.A., Roffwarg H.P. (1985) Alprazolam vs amitriptyline in depression with reduced REM latencies. Arch Gen Psychiatry 42:1154-1159.
Serre C., Clerc G., Escande M., Feline A., Ginestet D., Tignol J., Van Amerongen P. (1986) An early clinical trial of midalcipran, a potential fourth generation antidepressant. Curr Ther Res 39:156-164.
Spitzer R.L., Endicott J., Robins E. (1978) Research Diagnostic Criteria: rationale and reliability. Arch Gen Psychiatry 34:773-778.
Stenger A., Couziner J.P., Briley M. (1987) Psychopharmacology of midalcipran, l-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F 2207), a new potential antidepressant. Psychopharmacology 91:147-153.
Van Praag H.M. (1984) Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol Bull 20:599-602.
Warner M.D., Peabody C.A., Whiteford H.A., Hollister L.E. (1988) Alprazolam as an antidepressant. J Clin Psychiatry 49:148-150.